RxDoctor Payments Data

Laura Stewart

Family · Athens, ALNPI 1831424761

Payments from drug & device makers

$2,077in general payments, 2019–2025

Across 111 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$581
  • Pfizer$184
  • Bristol Myers Squibb$162
  • Sage Therapeutics, LLC$151
  • Urovant Sciences Inc$136
  • Daiichi Sankyo Inc.$130
  • plus $732 from 16 others

What the payments were for

  • Food & beverage$1,77886%
  • Education$29814%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,077 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$13,744
Medicare patients
84
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron48$41,244
MyrbetriqMirabegron40$29,872
ProliaDenosumab11$19,398
Estradiol181$8,825
PremarinEstrogens, Conjugated15$6,288
Estradiol (Twice Weekly)Estradiol11$1,906
Solifenacin Succinate30$1,476
Raloxifene Hcl20$1,378
YuvafemEstradiol11$1,357
ValacyclovirValacyclovir Hcl40$1,209
Clobetasol Propionate22$1,129
Metronidazole18$571
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$350
Alendronate Sodium38$346
Terconazole12$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$96$41,24448 claims
Astellas Pharma US IncMyrbetriq$581$29,87240 claims
PfizerPremarin$184$6,28815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,415 family providers in Alabama.

Other family in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →